Abstract
We report a COVID19 case with acute heart and kidney failure in a healthy young male. Echocardiography showed severe systolic and diastolic left ventricle dysfunction, with diffuse myocardial thickening. Cardiac MRI showed aspects of focal myocarditis, and hypertensive cardiomyopathy. Renal biopsy demonstrated limited acute tubular injury, and hypertensive kidney disease. Coronary angiography excluded critical stenoses. Unlike what we initially suspected, myocardial inflammation had a limited extent in our patient; severe hypertension causing cardiomyopathy and multi-organ damage, not diagnosed before, was primarily responsible for severe illness. Correct diagnosis and guidelines-directed treatment allowed a favorable course.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is at the moment an international public health emergency, caused by a novel enveloped RNA beta-coronavirus, named ‘severe acute respiratory syndrome coronavirus-2’ (SARS-CoV-2). The infection is mainly characterized by respiratory tract symptoms, presenting as mild flu-like illness to potentially lethal acute respiratory distress syndrome or fulminant pneumonia, but relevant cardiovascular complications and multi-organ failure can occur in severe cases [1]. Patients with known cardiovascular disease and risk factors appear more vulnerable to the infection, and hypertension is highly prevalent in patients who develop severe illness. Pathological mechanism underlying this association in still not completely elucidated: binding of the virus to angiotensin-converting enzyme 2 receptor (ACE-2), highly expressed on endothelial surfaces, with consequent renin-angiotensin-aldosterone system deregulation, and cytokine storm seem to have a relevant role [2].
We report a case of acute HF and documented cardiac inflammation during COVID-19. Multi-modality cardiac imaging and a challenging interdisciplinary medical approach lead to a de-novo diagnosis of hypertensive multi-organ damage, exacerbated by concomitant viral infection.
CASE PRESENTATION
A 45-years old man presented to our emergency department in April 2020 for atypical chest pain, fever and worsening effort dyspnoea from 7 days before. His past medical history was unremarkable and he denied alcohol and/or drugs abuse. On his arrival high blood pressure (BP = 180/110 mmHg), bi-basal pulmonary rales and mild leg swelling were detected; oxigen saturation was 93% while breathing ambient air. Electrocardiography showed sinus tachycardia with left axis deviation, slight diffuse ST depression more prominent in inferior-lateral leads (Fig. 1A ). Blood tests revealed a significant increase in Troponin T (82 ng/L; being 14 ng/L the upper reference limit of normal - URL), serum creatinine (3.1 mg/dl; eGFR 20 ml/min ml/min/1.73m2) and C-reactive protein (30 mg/L; being 5 mg/L the URL). At blood cell count, neutrophils were slightly augmented and lymphocytes slightly diminished. Nasopharyngeal swab was positive for SARS-CoV-2 infection. Chest X-rays and High resolution computed tomography scan of the lungs showed ground glass-like hyper density opacities limited to the peripheral portions of inferior lobes bilaterally, and a small area of consolidation in the left superior lobe (Figure 1B, 1C ). Transthoracic echocardiography was also performed and showed mild increase in LV dimension (end diastolic diameter: 57 mm; end diastolic volume: 141 ml, 83 ml/m2 BSA) and moderate increase in walls thickness (interventricular septum = 13.5 mm; posterior wall = 11 mm), with a sparkling appearance. LV ejection fraction (LVEF) was severely reduced because of a diffuse parietal hypokinesis (LVEF = 30%; quantified by Simpson’s method). Left atrium was moderately enlarged (area = 29 cm2), and the mitral diastolic filling pattern was restrictive. There was a mild mitral and tricuspid regurgitation and a mild pericardial effusion was noted behind the inferior-lateral LV wall.
A few hours after admission to our cardiac intensive care unit, patient’s condition degenerated abruptly; he presented BP elevation to 210/130 mmHg and respiratory failure, requiring nitroglycerin infusion, high doses of intravenous furosemide and non-invasive ventilatory support with continuous positive airway pressure (CPAP) of 10 cm H20. From the next days, clinical conditions began to improve, allowing removal of CPAP on day 3. Therapy with bisoprolol was initiated and gradually titrated up to 3.75 mg/die; amlodipine 10 mg/die and Alfuzosine 2 mg bid were also introduced for BP control. For viral infection, idroxichloroquine (200 mg bid) and darunavir/ritonavir (800/100 mg od) were administered for 10 and 5 days respectively according to local protocol. Feverish episodes (temperature > 38°C) persisted for the first 4 days. Clinical laboratory tests trend during hospitalization is summarized in Table 1 . Notably, serum creatinine remained constantly elevated; there was modest proteinuria (228 mg/L), without Bence-Jones proteinuria; serum and urine protein immunofixation excluded monoclonal free light chains.
When patient’s clinical conditions were stable, echocardiogram was repeated and confirmed diffuse parietal hypokinesis with improvement in LV systolic and diastolic function (LVEF = 38% and ‘pseudonormal’ diastolic filling pattern) (Figure 2) . Diffuse myocardial thickening was still evident. 2D Speckle-tracking showed diffuse reduction of global longitudinal strain, more severe in anterior segments, and partial apical sparing. Cardiac magnetic resonance imaging (MRI) was performed, showing increased symmetric and circumferential wall thickness, with diffuse LV hypokinesis (LVEF 35%) and mild hypokinesis of right ventricle (RVEF 41%). Short tau inversion recovery and T2-Mapping sequences demonstrated the presence of focal myocardial edema, in medium and apical segments of anterior wall and anterior septum. Phase-sensitive inversion recovery sequences showed a diffuse and intramural late gadolinium enhancement (LGE) of LV myocardium in all segments, with circumferential distribution. Pericardial effusion was not present (Figure 3 ). This pattern resulted appeared consistent with hypertensive cardiomyopathy, and myocarditis of limited extent. The day after, the patient underwent cranial computed tomography, showing multiple ischemic lacunar foci of the basal ganglia bilaterally, a stabilized ischemic lesion of the right corona radiata and white matter hypodensity (Supplementary files, figure 1) . Doppler ultrasound excluded clinically relevant carotid stenosis, and significant renal arteries pathology. Renal biopsy demonstrated diffuse acute tubular injury and modest chronic interstitial inflammation, with minimal tubulitis. Severe arteriolar hyalinosis (also in preglomerular arterioles), glomerular capsular thickening and capillary basement membrane wrinkling and duplication were also present, as for chronic hypertensive kidney disease (figure 4 ). Amyloid deposits were excluded. Fifteen days after admission, the patient was discharged. One month later, after clinical and biochemical resolution of COVID-19 as demonstrated by two consecutive negative nasopharyngeal swabs, he was readmitted in our Unit for coronary angiography control. This showed diffuse atherosclerotic disease of epicardial vessels without critical stenoses (Supplementary files, Figure 2 ). A new echocardiogram demonstrated further reduction of LV volumes with improvement in EF (to 46%). Renal function was persistently impaired (serum creatinine: 2.9 mg/dl). Cardiac MRI performed 2 month later, showed a reduction in biventricular volumes with improvement in LVEF up to 50%; LV parietal hypertrophy was unchanged (septal thickness: 13 mm) with mild, diffuse intramural LGE; T1 and T2 sequences showed resolution of edema.
DISCUSSION
The present report describes a case of COVID 19 with acute respiratory failure, acute myocardial and kidney injury, in a patient firstly diagnosed with severe hypertension causing dilated cardiomyopathy and multiple target-organ damage. Definite diagnosis was possible through myocardial and renal tissue characterization. Notably, they were both obtained in a living patient with severe COVID 19, the first through cardiac magnetic resonance, the latter by means of kidney biopsy.
Preexisting CV disease were found to be independent predictor of in-hospital mortality in COVID-19 patients [1,2]. Moreover, severe illness may be complicated by acute myocardial injury, clinically expressed by cardiac troponin release, electrocardiographic abnormalities and myocardial dysfunction [3]. Cardiac involvement may occur due to ischemic (acute myocardial ischemia/infarction) or non-ischemic processes, including stress-induced cardiomyopathy and myocarditis.
Several cases of acute heart failure or cardiogenic shock caused with echo-documented and MRI-proven myocardial inflammation due to COVID-19 have been published so far [4, 5, 6]; cardiac MRI showed diffuse, extensive myocardial edema conditioning global cardiac function impairment. In our case, echocardiography during hospitalization showed diffuse myocardial thickening, with an echo-bright appearance, severe diastolic dysfunction with initially restrictive filling pattern, bi-atrial enlargement and mild pericardial effusion. Moreover, global longitudinal strain with partial apical sparing was detected at 2D-speckle tracking. These aspects aroused at first the suspect of a possible infiltrative cardiomyopathy, as amyloidosis. Other diagnostic hypothesis were: extensive COVID-19 related myocardial inflammation with diffuse interstitial infiltrates, or misdiagnosed hypertensive cardiomyopathy. Systemic amyloidosis was also at first suggested by the presence of kidney failure, but this hypothesis was later rejected on the basis of serum and urine immunofixation. Cardiac MRI was crucial in the diagnostic process; it confirmed diffuse myocardial thickening and systolic impairment; myocardial edema depicted by T1 and T2 sequences had a limited extent, thus suggesting that the severe cardiac impairment was not exclusively caused by myocarditis. LGE pattern appeared non suggestive for amyloidosis and supported the diagnosis of hypertensive cardiomyopathy. Interestingly, cardiac function gradually improved during and after hospitalization, in parallel with COVID-19 resolution and effective treatment of hypertension.
Kidney impairment is frequent in COVID-19 patients: more than 40% of them have proteinuria at hospital admission [7], while some critically ill patients may develop during hospitalization an acute kidney injury (AKI) [8]. The most common pathogenic factors appear related to direct renal injury (promoted by the binding of SARS-CoV-2 to ACE-2 on tubular cells and podocytes), to microthrombi formation due to hypercoagulability, and to the effects of acute systemic inflammatory response[8]. Kidney biopsy findings in our patient revealed diffuse acute tubular damage with modest interstitial inflammation, as for AKI, together with glomerular and vascular alterations consistent with chronic hypertensive nephropathy. Resolution of infective process however did not lead to a significant improvement of kidney function, thus we can speculate that in this patient the long-time undiagnosed severe hypertension was the main contributor to his kidney impairment. Cranial CT findings, suggestive for hypertensive encephalopathy, were also in keeping with a severe uncontrolled hypertension not diagnosed before.
In conclusion, our report depicts how a condition of severe, untreated hypertension can increase cardiac vulnerability to COVID-19 infection: acute inflammatory alterations, even of limited extent, may critically destabilize a preexisting organ damage of hypertensive etiology, leading to a condition of severe HF. This report highlights that in these patients the same mechanistic approach to cardiac and systemic abnormalities should be used, increasing utilization of multi-modality imaging and diagnostic tools that may help us to make a correct diagnosis.